In an astrocytoma model, it was shown that out of 133 tumors, 10% of low-grade tumors were positive for the AT1 receptor, versus 67% for high-grade tumors; 17% of low-grade tumors were positive for the AT2 receptor, versus 53% for high-grade tumors [113]. This evidence concerns the gene AGTR2 and astrocytoma (excluding glioblastoma).